Viking Obesity Pill Faces Steep Climb Against Lilly's Tirzepatide, Analyst Calls Downtrend Reaction 'Extreme'

Why is Tesla under federal crash report investigation? How will US-EU trade deal impact tariffs? Why did Cracker Barrel shares plunge recently? What caused Meta to freeze AI hiring? How are tariffs affecting US retailers like Walmart? Why is Fed Governor Lisa Cook facing DOJ probe? What factors are shaping Powell's Jackson Hole speech?

Viking Obesity Pill Faces Steep Climb Against Lilly's Tirzepatide, Analyst Calls Downtrend Reaction 'Extreme'

benzinga.com/analyst-stock-ratings/analyst-color/25/08/47218485/viking-obesity-pill-faces-steep-climb-against-lillys-tirzepatide-analyst-call

Investors appear disappointed with Viking Therapeutics Inc.’s (NASDAQ:VKTX) data from its Phase 2 trial of an obesity pill.
Participants receiving once-daily doses of oral VK2735 demonstrated a mean body weight reduction of up to 12.2% after 13 weeks from baseline.
Participants receiving…

This story appeared on benzinga.com, 2025-08-19 18:44:39.